Hematopoietic Stem Cell Mobilization in Idiopathic CD4 Lymphocytopenia Patients and Healthy Controls for the Study of T Cell Maturation and Trafficking in Murine Models

NCT02015013 · clinicaltrials.gov ↗

PHASE2

Phase

RECRUITING

Status

40

Enrollment

NIH

Sponsor class

Conditions

Idiopathic CD4-Positive
T-Lymphocytopenia

Interventions

BIOLOGICAL: Filgrastim
DRUG: Plerixafor

Sponsor

National Institute of Allergy and Infectious Diseases (NIAID)